JenaValve's Trilogy Transcatheter Heart Valve, the only TAVR device approved by the FDA for treating aortic regurgitation, may offer hope for high-risk LVAD patients in need of aortic valve replacement. Additional follow-up data are still necessary, researchers emphasized.